Ryohei Yamamoto
Direktor/Vorstandsmitglied bei Titan, Inc. (Japan)
Profil
Mr. Ryohei Yamamoto is on the Board of Directors at Tella Pharma, Inc., Titan, Inc. (Japan), and tella, Inc.
Aktive Positionen von Ryohei Yamamoto
| Unternehmen | Position | Beginn |
|---|---|---|
Titan, Inc. (Japan)
 Titan, Inc. (Japan) Data Processing ServicesTechnology Services Titan, Inc. provides imaging solutions and clinical trial support services. The company was founded on May 2, 2013 and is headquartered in Tokyo, Japan. | Direktor/Vorstandsmitglied | 01.05.2013 |
Ehemalige bekannte Positionen von Ryohei Yamamoto
| Unternehmen | Position | Ende |
|---|---|---|
| TELLA, INC. | Verwaltungsdirektor | 13.06.2012 |
Tella Pharma, Inc.
 Tella Pharma, Inc. Medical SpecialtiesHealth Technology Founded in 2014, Tella Pharma, Inc. is a Japanese company that manufactures clinical test equipment. The company is based in Tokyo, Japan. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Titan, Inc. (Japan)
Titan, Inc. (Japan) Data Processing ServicesTechnology Services Titan, Inc. provides imaging solutions and clinical trial support services. The company was founded on May 2, 2013 and is headquartered in Tokyo, Japan. | Technology Services |
Tella Pharma, Inc.
Tella Pharma, Inc. Medical SpecialtiesHealth Technology Founded in 2014, Tella Pharma, Inc. is a Japanese company that manufactures clinical test equipment. The company is based in Tokyo, Japan. | Health Technology |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
